Tianjin Zhongxin Pharmaceutical Group Corporation

Results

Tianjin Zhongxin Pharma's 1Q earnings rise 30% to $36.3 mil on higher margins

SINGAPORE (Apr 27): Tianjin Zhongxin Pharmaceutical Group announced earnings of RMB173.4 million ($36.3 million) for the first quarter ended March, up 30% from its 1Q17 earnings of $133.8 million a year ago on improved gross profit margins.

Broker's Calls

Tianjin Zhongxin Pharma on its way to a stellar 2018 & beyond, says UOB

SINGAPORE (Apr 2): UOB Kay Hian is keeping Tianjin Zhongxin Pharmaceutical Group at “buy” with a higher target price of US$1.66 ($2.17), pegged to peer average of 14.1 times FY18 earnings.
×